

# Alcoholic Hepatitis: Diagnosis and Management

Michelle Keating, DO, MEd; Olivia Lardo, MD; and Maggie Hansell, MD

Wake Forest School of Medicine, Winston-Salem, North Carolina

Alcoholic hepatitis is a clinical syndrome characterized by acute-onset jaundice and liver enzyme abnormalities in the setting of long-term heavy alcohol use. High rates of concomitant infections, systemic inflammation, and multiorgan failure lead to significant morbidity and mortality. Diagnosis of alcoholic hepatitis is primarily clinical, based on a consensus definition from the National Institute on Alcohol Abuse and Alcoholism. Initial workup should include chest radiography and cultures of peritoneal fluid, blood, and urine. Close monitoring for inflammation and organ failure is crucial throughout hospitalization. Laboratory-based prognostic scores, including Maddrey Discriminant Function and the Model for End-Stage Liver Disease, help determine disease severity and treatment options. Treatment for moderate disease primarily consists of supportive care, including alcohol cessation and nutritional support. Corticosteroids are recommended for severe alcoholic hepatitis. Responsiveness to corticosteroid therapy should be evaluated using the Lille score on day 7 of treatment. Hospital physicians should involve a multidisciplinary team, including substance abuse specialists, gastroenterologists or hepatologists, nephrologists, dietitians, and intensivists, as appropriate. Long-term follow-up should focus on abstinence from alcohol, management of underlying cirrhosis, and evaluation for liver transplantation if indicated. Pharmacologic treatment of alcohol use disorder can aid patients in maintaining abstinence from alcohol. The presence of underlying cirrhosis and continued alcohol use negatively impact long-term prognosis. (*Am Fam Physician*. 2022;105(4):412-420. Copyright © 2022 American Academy of Family Physicians.)

**Alcohol-associated** liver disease encompasses a range of pathologies from hepatic steatosis to cirrhosis. Decompensated liver disease can manifest as ascites, variceal hemorrhage, hepatic encephalopathy, spontaneous bacterial peritonitis, hepatorenal syndrome, hepatopulmonary syndrome, or hepatocellular carcinoma. Alcoholic hepatitis is a clinical syndrome associated with acute-onset jaundice and liver failure.<sup>1</sup> High rates of concomitant infections, systemic inflammation, and multiorgan failure lead to significant morbidity and mortality.

## Epidemiology and Risk Factors

The incidence of alcoholic hepatitis is difficult to estimate because of inconsistency in diagnosis of the disease and overlap with concurrent, more easily diagnosed liver diseases, such as hepatitis C.<sup>1,2</sup> However, hospital admissions for

alcoholic hepatitis are on the rise in the United States, accounting for 0.83% of all admissions in 2010.<sup>1</sup> Risk factors for the development of the disease include prolonged and heavy alcohol use, younger age, female sex, genetic susceptibility, higher body mass index, and comorbid liver disease.<sup>1,3-5</sup> Overall and in-hospital mortality are high for severe alcoholic hepatitis, with a 28-day mortality rate of 16% to 30% and a one-year mortality rate of 56%.<sup>6</sup> The presence of underlying cirrhosis and continued alcohol use negatively impact long-term prognosis.<sup>4,7-9</sup>

## Diagnosis

Because of historical variability in the diagnosis of alcoholic hepatitis, the National Institute on Alcohol Abuse and Alcoholism developed a consensus statement for diagnosing the disease (Table 1).<sup>1,7,10</sup> The diagnosis is primarily clinical and must include acute-onset jaundice, specific laboratory abnormalities, and characteristic history of alcohol use (i.e., long-term consumption of roughly three standard drinks daily for women and four standard drinks daily for men). Liver biopsy is necessary only if the

**CME** This clinical content conforms to AAFP criteria for CME. See CME Quiz on page 358.

**Author disclosure:** No relevant financial relationships.

Clinical recommendation	Evidence rating	Comments
Use laboratory-based prognostic tools, including the Maddrey Discriminant Function, Model for End-Stage Liver Disease, and Lille scores, to determine severity and prognosis of alcoholic hepatitis and treatment options. <sup>1,7,19,21</sup>	C	Guidelines, RCT, and cohort studies
Promote long-term abstinence from alcohol for all patients with alcoholic hepatitis. <sup>1,11,12,25,26</sup>	B	Consistency across guidelines and cohort studies
Provide nutritional support for patients with alcoholic hepatitis, with a daily energy intake of 35 to 40 kcal per kg of body weight and a daily protein intake of 1.2 to 1.5 g per kg of body weight. <sup>12,25,28-30</sup>	C	Consensus guidelines and an RCT
Administer corticosteroids to patients with severe alcoholic hepatitis without active infection. <sup>1,12,22,25,31,32</sup>	A	Guidelines based on RCTs and meta-analysis of RCTs
Evaluate the response to corticosteroid therapy in alcoholic hepatitis using the Lille score at day 7 of treatment. <sup>1,18,24,32</sup>	B	Guideline and prospective cohort study

RCT = randomized controlled trial.

A = consistent, good-quality patient-oriented evidence; B = inconsistent or limited-quality patient-oriented evidence; C = consensus, disease-oriented evidence, usual practice, expert opinion, or case series. For information about the SORT evidence rating system, go to <https://www.aafp.org/afpsort>.

TABLE 1

### Consensus Definition of Alcoholic Hepatitis

#### Diagnostic criteria

Jaundice onset within previous 8 weeks

Long-term consumption of alcohol: > 40 g (roughly 3 standard drinks) daily for women or > 60 g (roughly 4 standard drinks) daily for men for  $\geq 6$  months, with < 60 days of abstinence before onset of jaundice

AST > 50 U per L (0.83  $\mu$ kat per L), AST/ALT ratio > 1.5, and both AST and ALT < 400 U per L (6.68  $\mu$ kat per L)

Total bilirubin > 3 mg per dL (51.31  $\mu$ mol per L)

Absence of confounding factors

#### Confounding factors

Possible ischemic hepatitis (suggested by severe upper gastrointestinal tract bleed, hypotension, cocaine use within seven days of symptom onset)

Possible metabolic liver disease (Wilson disease, alpha<sub>1</sub>-antitrypsin deficiency)

Possible drug-induced liver disease (use of offending drug within 30 days of jaundice onset)

Uncertain alcohol use assessment (patient denies excessive alcohol use)

Atypical laboratory findings (AST < 50 U per L or > 400 U per L, AST/ALT ratio < 1.5, antinuclear antibodies > 1:160, or anti-smooth muscle antibodies > 1:80)

If diagnostic confirmation would change management in the presence of confounding factors, perform liver biopsy

ALT = alanine transaminase; AST = aspartate transaminase.

Information from references 1, 7, and 10.

diagnosis is unclear and accurate diagnosis would impact management.<sup>7,10</sup>

### CLINICAL PRESENTATION AND LABORATORY FINDINGS

Acute onset of jaundice is the only clinical sign or symptom required for the diagnosis of alcoholic hepatitis.<sup>7,10</sup> However, other nonspecific signs and symptoms (*Table 2*,<sup>11,12</sup> and *Figure 1*) can support the diagnosis of alcoholic hepatitis and suggest underlying chronic alcohol-associated liver disease. Because these signs and symptoms can be subtle, a high index of suspicion is required. Laboratory findings that are diagnostic for alcoholic hepatitis or characteristic of alcohol-associated liver disease are outlined in *Table 2*,<sup>11,12</sup>; deviation from the specified diagnostic pattern should prompt consideration of alternative diagnoses.

### CHARACTERISTIC ALCOHOL USE HISTORY

Presence of the characteristic alcohol use history is an important component of the clinical diagnosis, and patient reluctance to disclose alcohol use is a significant issue.<sup>13</sup> Validated screening tools (*Table 3*,<sup>10,14-17</sup>) and collateral history from family members can aid in identifying high-risk alcohol use.<sup>1</sup> The Alcohol Use Disorders Identification Test-Concise screening questionnaire is a more targeted screening tool for identifying alcohol misuse than the CAGE (cut down, annoyed, guilty, eye-opener) questionnaire.<sup>14</sup>

Blood and urine alcohol biomarkers (*Table 3*,<sup>10,14-17</sup>) can be used to prompt a discussion about alcohol use, support the diagnosis of alcoholic hepatitis, and aid in the patient's recovery.<sup>1</sup> Clinicians should discuss the significance of biomarkers with patients before and after testing.


**FIGURE 1****Signs and symptoms of alcoholic hepatitis and liver disease.**

Illustration by Scott Bodell

## RULING OUT CONFOUNDING AND CONCOMITANT DIAGNOSES

Because of significant overlap in presenting symptoms of alcoholic hepatitis and other diagnoses, a thorough history, laboratory studies, and imaging tests should be performed to rule out confounding and concomitant diagnoses (Table 4).<sup>1,10,12</sup> Testing for infections is crucial in the initial management of patients with suspected alcoholic hepatitis.<sup>1</sup> The disease is most commonly associated with spontaneous bacterial peritonitis, urinary tract infection, pneumonia, enterocolitis, and cellulitis.<sup>1,12</sup>

## Risk Stratification

After establishing the diagnosis of alcoholic hepatitis, clinicians should use validated laboratory-based prognostic tools (Table 5)<sup>18-24</sup> to determine severity, prognosis, and treatment options. Severe alcoholic hepatitis is defined as a score of at least 32 using the Maddrey Discriminant Function tool (<https://www.mdcalc.com/maddreys-discriminant-function-alcoholic-hepatitis>) or at least 21 using the Model for End-Stage Liver Disease tool (<https://www.mdcalc.com/meld-score-model-end-stage-liver-disease-12-older> or <https://www.mdcalc.com/meldna-meld-na-score-liver-cirrhosis>).<sup>7</sup> The Lille score

**TABLE 2**

### Symptoms and Laboratory Findings Suggestive of Alcoholic Hepatitis and Alcohol-Associated Liver Disease

#### Symptoms

- Abdominal pain (right upper quadrant, epigastric)
- Anorexia
- Confusion (encephalopathy)
- Fatigue
- Fever
- Malaise
- Nausea and vomiting
- Peripheral neuropathy
- Sleep-wake inversion
- Weight gain (ascites)
- Weight loss (loss of muscle mass, malnutrition)

#### Laboratory tests

- Diagnostic findings
  - AST > 50 U per L (0.83 µkat per L)
  - AST/ALT ratio > 1.5
  - AST and ALT < 400 U per L (6.68 µkat per L)
  - Total bilirubin > 3 mg per dL (51.31 µmol per L)
- Other characteristic findings
  - Decreased serum albumin and prealbumin
  - Elevated gamma-glutamyltransferase

#### Laboratory tests (continued)

- Other characteristic findings (continued)
  - Elevated international normalized ratio
  - Elevated white blood cell count with neutrophil predominance
  - Macrocytosis
  - Thiamine deficiency
  - Thrombocytopenia
  - Vitamin B<sub>12</sub> and/or folate deficiency

**Note:** See Figure 1 for an illustration of common signs and symptoms.

ALT = alanine transaminase; AST = aspartate transaminase.

Information from references 1, 11, and 12.

(<https://www.mdcalc.com/lille-model-alcoholic-hepatitis>) distinguishes patients who would likely be responsive vs. unresponsive to steroids, predicting who could have poorer outcomes if steroid therapy was continued beyond seven days.<sup>18</sup>

## Management

Figure 2 is an algorithm for the diagnosis and treatment of alcoholic hepatitis.

### ABSTINENCE FROM ALCOHOL

Abstinence from alcohol is the mainstay of treatment. Clinicians should counsel all patients on alcohol cessation, offer medications for alcohol use disorder when appropriate, and consider early consultation with a substance abuse counselor, social worker, and/or psychiatrist, depending on institutional resources.<sup>1,25,26</sup>

If resources for alcohol use disorder are not readily available, referral to a center with expertise in this disorder should be considered.<sup>1,12</sup>

During inpatient management, using a structured alcohol withdrawal protocol in conjunction with a standard instrument such as the Clinical Institute Withdrawal Assessment for Alcohol Revised (<https://www.mdcalc.com/ciwa-ar-alcohol-withdrawal>) to guide benzodiazepine dosing can prevent withdrawal symptoms, including delirium tremens and seizures.<sup>27</sup> Because benzodiazepines can precipitate or worsen hepatic encephalopathy and possibly impair liver function, the dosage should be limited to the minimum needed for symptom control.

### NUTRITIONAL SUPPORT

Protein-calorie malnutrition is a common comorbidity to alcohol-associated liver disease and alcoholic hepatitis as a result of decreased nutritional intake, decreased gut absorption, and catabolic metabolism. Because poor nutrition is associated with worse outcomes, dietitian consultation should be considered.

Nutritional support can include low-volume intravenous fluids for dehydration; intravenous or oral thiamine to decrease risk of Wernicke

encephalopathy; and supplemental folate, vitamin B<sub>6</sub>, vitamin B<sub>12</sub>, and zinc for common vitamin deficiencies.<sup>1,28</sup> Daily energy intake of 35 to 40 kcal per kg of body weight and daily protein intake of 1.2 to 1.5 g per kg of body weight are recommended.<sup>12,25,28-30</sup>

Nasogastric tube placement for enteral feedings can be considered if the patient is unable to eat orally; however, this is often poorly tolerated, and oral nutrition is preferred. Parenteral nutrition increases the risk of infection and liver injury, and there is no evidence supporting its use in patients with alcoholic hepatitis.<sup>30</sup> As patients with severe malnutrition begin enteral feedings, close attention to electrolyte levels, including sodium, potassium, phosphate, and magnesium, is required to avoid refeeding syndrome, a potentially dangerous shift in fluids and electrolytes.<sup>28,30</sup>

TABLE 3

### Alcohol Use Screening Tests

Test	Comments
<b>Screening questionnaires</b>	
Alcohol Use Disorders Identification Test-Concise <sup>14</sup>	Three-question screen (frequency of alcohol use, number of drinks in one sitting, frequency of ≥ 6 drinks in one sitting), with tiered point system depending on response; online calculator available at <a href="https://www.mdcalc.com/audit-c-alcohol-use">https://www.mdcalc.com/audit-c-alcohol-use</a> Men with a score ≥ 4: sensitivity = 86%, specificity = 89% Women with a score ≥ 3: sensitivity = 73%, specificity = 91%
National Institute on Alcohol Abuse and Alcoholism Single Alcohol Screening Question <sup>15</sup>	"How many times in the past year have you had five or more drinks in one day (for men) or four or more drinks in one day (for women)?" Sensitivity = 80%, specificity = 74%
<b>Biomarkers</b>	
Ethyl glucuronide or ethyl sulfate <sup>16</sup>	Urine alcohol biomarker that detects use in the preceding three days Prolonged by renal insufficiency Ethyl glucuronide: sensitivity = 76%, specificity = 93% Ethyl sulfate: sensitivity = 82%, specificity = 86%
Phosphatidylethanol <sup>17</sup>	Blood alcohol biomarker that detects use in the preceding two to three weeks Not affected by age, body mass index, patient sex, kidney disease, or liver disease More costly than urine tests Sensitivity = 100%, specificity = 96%

Information from references 10 and 14-17.

**TABLE 4****History and Diagnostic Testing to Rule Out Concomitant or Confounding Diagnoses in Patients With Alcoholic Hepatitis**

Diagnosis	Tests/findings
Autoimmune liver disease	Antinuclear antibodies > 1:160, anti-smooth muscle antibodies > 1:80
Biliary obstruction	Right upper quadrant ultrasonography or abdominal computed tomography with contrast
Drug-induced liver injury	Assess for offending drug exposure, including acetaminophen levels, within 30 days of jaundice onset
Infection	Blood cultures, chest radiography, peritoneal fluid cultures if ascites is present, urinalysis and urine culture
Ischemic hepatitis	Urine drug screening Assess for presence of severe upper gastrointestinal tract bleeding, hypotension, and cocaine use within seven days of symptom onset
Metabolic liver disease	Alpha <sub>1</sub> -antitrypsin deficiency, hemochromatosis (high ferritin level), Wilson disease (low ceruloplasmin level)
Viral hepatitis	Viral hepatitis panel

Information from references 1, 10, and 12.

**MEDICATION MANAGEMENT**

Given the high rate of concomitant infections in patients with alcoholic hepatitis, it is reasonable to administer broad-spectrum empiric antibiotics while awaiting culture results.<sup>1,25</sup> After workup and culture findings rule out alternative diagnoses and any infections have been treated successfully, guidelines support initiating oral corticosteroids (prednisolone, 40 mg per day, or methylprednisolone, 32 mg per day) in patients with severe alcoholic hepatitis. However, the benefit of corticosteroids is questionable, and treatment should be limited to 28 days (with or without taper over three weeks) based on randomized controlled trials and meta-analyses.<sup>1,12,22,25,31,32</sup>


**TABLE 5****Validated Laboratory-Based Prognostic Scores for Alcoholic Hepatitis**

Score	Components	Thresholds	Clinical significance
Lille Model for Alcoholic Hepatitis	Day 0: age, albumin, INR, creatinine, bilirubin, prothrombin time; day 7: bilirubin ( <a href="https://www.mdcalc.com/lille-model-alcoholic-hepatitis">https://www.mdcalc.com/lille-model-alcoholic-hepatitis</a> )	Patient unresponsive to steroids (score $\geq$ 0.45)	Discontinue corticosteroids at day 7 <sup>18</sup>
Maddrey Discriminant Function	Prothrombin time, total bilirubin ( <a href="https://www.mdcalc.com/maddreys-discriminant-function-alcoholic-hepatitis">https://www.mdcalc.com/maddreys-discriminant-function-alcoholic-hepatitis</a> )	Severe disease (score $\geq$ 32)	Initiate corticosteroids <sup>19</sup>
MELD	Bilirubin, creatinine, INR, sodium ( <a href="https://www.mdcalc.com/meld-score-model-end-stage-liver-disease-12-older">https://www.mdcalc.com/meld-score-model-end-stage-liver-disease-12-older</a> )	Severe disease (score $\geq$ 21)	Initiate corticosteroids Predicts increased risk of in-hospital mortality if increases $\geq$ 2 in one week <sup>20</sup> 90-day mortality of 20% (sensitivity and specificity = 75%) <sup>21</sup> 28-day mortality of 30% to 50% (sensitivity = 86%, specificity = 48%) <sup>19,22</sup>
MELD-Na	Bilirubin, creatinine, INR, sodium ( <a href="https://www.mdcalc.com/meldna-meld-na-score-liver-cirrhosis">https://www.mdcalc.com/meldna-meld-na-score-liver-cirrhosis</a> )	Transplant eligible (score $\geq$ 21)	Refer for liver transplant evaluation
Child-Pugh Score for Cirrhosis Mortality	Total bilirubin, albumin, INR, ascites burden, encephalopathy grade ( <a href="https://www.mdcalc.com/child-pugh-score-cirrhosis-mortality">https://www.mdcalc.com/child-pugh-score-cirrhosis-mortality</a> )	Class A: score 5 or 6 Class B: score 7 to 9 Class C: score 10 to 15	Describes cirrhosis severity; less commonly used for prognosis given the advantages of MELD <sup>23</sup>

INR = international normalized ratio; MELD = Model for End-Stage Liver Disease.

Information from references 1 and 18-24.

FIGURE 2



\*—Women: > 40 g (roughly 3 standard drinks) daily for ≥ 6 months. Men: > 60 g (roughly 4 standard drinks) daily for ≥ 6 months.

†—<https://www.mdcalc.com/maddreys-discriminant-function-alcoholic-hepatitis>.

‡—<https://www.mdcalc.com/meld-score-model-end-stage-liver-disease-12-older>.

§—<https://www.mdcalc.com/lille-model-alcoholic-hepatitis>.

#### Diagnosis and treatment of alcoholic hepatitis.

Corticosteroid use is associated with an increased risk of infections and gastrointestinal hemorrhage and can be harmful if administered to patients with unclear diagnoses, less severe disease, or concomitant infections.<sup>1,6,32</sup>

Corticosteroid use should be discontinued in patients who do not show an initial response (i.e., Lille score of 0.45 or more on day 7).<sup>1,18</sup> If the Lille score suggests responsiveness, the corticosteroid dose should be continued for a total of 28 days and then tapered. One study indicates that a Lille score on day 4 may be as accurate at predicting response to corticosteroids as on day 7.<sup>32,33</sup> Corticosteroids are not recommended for patients with moderate alcoholic hepatitis.<sup>1,32</sup>

Guidelines recommend intravenous *N*-acetylcysteine, 40 mg per day for five days, as an adjunct to corticosteroids in patients with severe alcoholic hepatitis.<sup>1,12,25,34</sup> Pentoxifylline is no longer recommended because of a lack of data demonstrating benefit.<sup>1,6,12,32</sup> Therapies targeting inflammation and oxidative stress, alcohol use disorder, and gut-liver axis dysfunction have shown early promise in the treatment of alcoholic hepatitis but require further study.<sup>8</sup>

#### EARLY LIVER TRANSPLANTATION

There is growing support for early liver transplantation in some patients with severe alcoholic hepatitis, rather than requiring six months of alcohol abstinence and engagement in alcohol cessation counseling. Patients with severe alcoholic hepatitis who are not responding to medical therapy (clinically or by Lille score) or are ineligible for medical therapy and are presenting with alcoholic hepatitis as their first liver-decompensating event may be candidates for early liver transplantation.<sup>1,4,12,25,32,35</sup> Assessment should include psychosocial evaluation by a multidisciplinary team, including a social worker, psychiatrist/addiction specialist, mental health professionals, and liver transplant teams, to identify candidates at minimal risk of returning to alcohol use after transplantation.<sup>1,4,12,25,35</sup>

#### GUIDELINE-DIRECTED TREATMENT OF COMORBIDITIES AND COMPLICATIONS

Decompensated cirrhosis can precipitate or result from alcoholic hepatitis. Patients should be monitored for signs of decompensation on physical examination and with daily laboratory testing. *Table 6* outlines guideline-directed

TABLE 6

**Guideline-Directed Treatment Recommendations for Comorbidities and Complications in Patients With Alcoholic Hepatitis**

Condition	Treatment recommendations
Acute kidney injury and hepatorenal syndrome	<p>Stop diuretics, beta blockers, nonsteroidal anti-inflammatory drugs, nephrotoxic drugs, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, and vasodilators</p> <p>Albumin (1 g per kg per day titrated to a maximum dosage of 100 g per day) for two days</p> <p>Therapeutic paracentesis for tense ascites with albumin infusion for any volume of fluid</p> <p>For hepatorenal syndrome: vasoactive drugs with albumin infusions</p> <p>Terlipressin (not available in the United States), octreotide (Sandostatin) and midodrine, or norepinephrine</p> <p>Albumin, 20 to 40 g per day</p> <p>Consider TIPS or renal replacement therapy</p>
Ascites	<p>Diagnostic paracentesis with blood cell counts, cultures, fluid protein measurement, Serum Ascites Albumin Gradient calculation*</p> <p>Sodium restriction (&lt; 2 g per day)</p> <p>Fluid restriction (1 to 1.5 L per day) if serum sodium &lt; 125 mEq per L (125 mmol per L)</p> <p>Diuretics (spironolactone with or without furosemide [Lasix])</p> <p>Spironolactone, 100 mg per day initially, then titrate by 100 mg every three days to a maximum dosage of 400 mg per day</p> <p>Furosemide, 40 mg per day titrated to a maximum dosage of 160 mg per day</p> <p>Avoid or adjust for severe hyponatremia (sodium &lt; 125 mEq per L), hypo- or hyperkalemia, acute kidney injury, severe cramps</p> <p>For tense or refractory ascites: therapeutic paracentesis with albumin replacement (6 to 8 g per L of ascites fluid) when 6 L or more is removed</p> <p>Prophylactic ciprofloxacin (400 mg per day) in patients with a Child-Pugh score <math>\geq 9</math> and bilirubin <math>\geq 3</math> mg per dL (51.31 <math>\mu</math>mol per L), impaired renal function or hyponatremia, and ascitic fluid protein &lt; 15 g per L</p> <p>Consider TIPS for recurrent or refractory ascites</p> <p>Treat precipitating factors</p>
Hepatic encephalopathy	<p>Lactulose titrated to produce two or three bowel movements per day</p> <p>Rifaximin (Xifaxan); short-term alternatives are neomycin and metronidazole (Flagyl)</p> <p>If patient does not respond to treatment, consider oral branched-chain amino acids or intravenous L-ornithine L-aspartate</p>
Spontaneous bacterial peritonitis	<p>Peritoneal and blood cultures before treatment initiation</p> <p>Diagnosis requires peritoneal fluid polymorphonuclear leukocyte count <math>&gt; 250</math> per <math>mm^3</math></p> <p>Antibiotics (third-generation cephalosporin; piperacillin/tazobactam [Zosyn] or carbapenems for resistance)</p> <p>Albumin (1.5 g per kg at diagnosis and 1 g per kg on day 3)</p> <p>Prophylactic ciprofloxacin after recovery</p>
Variceal hemorrhage	<p>Primary prevention of hemorrhage with nonselective beta blockers</p> <p>Avoid nonselective beta blockers during acute bleed</p> <p>Vasoactive drug therapy (somatostatin or octreotide) for three to five days</p> <p>Endoscopic ligation within 12 hours and after stabilization (preprocedure erythromycin)</p> <p>Antibiotic prophylaxis with ceftriaxone or quinolones for up to seven days</p> <p>Restrictive transfusion strategy with a hemoglobin goal <math>&gt; 7</math> g per dL (70 g per L)</p> <p>Consider TIPS</p>

TIPS = transjugular intrahepatic portosystemic shunt.

\*An online calculator for the Serum Ascites Albumin Gradient is available at <https://www.mdcalc.com/serum-ascites-albumin-gradient-saag>.

†An online calculator for the Child-Pugh Score for Cirrhosis Mortality is available at <https://www.mdcalc.com/child-pugh-score-cirrhosis-mortality>.

Information from references 11 and 36-40.

TABLE 7

**Indications for Consideration of Liver Transplantation in Alcoholic Hepatitis**

- Diagnosis of hepatocellular carcinoma
- Episode of spontaneous bacterial peritonitis
- Model for End-Stage Liver Disease-Na score  $\geq 21$  (<https://www.mdcalc.com/meldna-meld-na-score-liver-cirrhosis>)
- New-onset decompensation (ascites, encephalopathy, jaundice, or variceal hemorrhage)
- Patients with alcohol-associated liver disease who do not improve after 3 months of abstinence, especially with a class C (10 to 15 points) Child-Pugh Score for Cirrhosis Mortality (<https://www.mdcalc.com/child-pugh-score-cirrhosis-mortality>)

Information from reference 1.

and disease management). Guidelines were consulted from the American Association for the Study of Liver Diseases, National Institute on Alcohol Abuse and Alcoholism, European Association for the Study of the Liver, American Gastroenterological Association, U.S. Preventive Services Task Force, and European Society for Clinical Nutrition and Metabolism. Reference lists from retrieved sources were also searched. Search dates: April 19, 2021, and February 1, 2022.

**The Authors**

**MICHELLE KEATING, DO, MEd**, is director of the Academic Family Medicine Fellowship and an assistant professor in the Department of Family and Community Medicine at the Wake Forest School of Medicine, Wake Forest Baptist Medical Center, Winston-Salem, N.C.

**OLIVIA LARDO, MD**, is a resident in the Department of Family and Community Medicine at the Wake Forest School of Medicine.

**MAGGIE HANSELL, MD**, is the inpatient medical director and an assistant professor in the Department of Family and Community Medicine at the Wake Forest School of Medicine.

Address correspondence to Michelle Keating, DO, MEd, Wake Forest Baptist Medical Center, 1920 W. 1st St., Winston-Salem, NC 27104 (email: [mkeating@wakehealth.edu](mailto:mkeating@wakehealth.edu)). Reprints are not available from the authors.

**References**

1. Crabb DW, Im GY, Szabo G, et al. Diagnosis and treatment of alcohol-associated liver diseases: 2019 practice guidance from the American Association for the Study of Liver Diseases. *Hepatology*. 2020;71(1):306-333.
2. Verry J, Forrest EH. Recent advances in alcoholic hepatitis. *Frontline Gastroenterol*. 2019;11(2):133-139.
3. Hosseini N, Shor J, Szabo G. Alcoholic hepatitis: a review. *Alcohol*. 2019;54(4):408-416.
4. Bhatti S, Kim D, Ahmed A, et al. Current trends in liver transplantation for alcoholic hepatitis. *Clin Liver Dis*. 2021;25(3):625-634.
5. Morgan MY, Sharma M, Atkinson SR. Genetic and environmental susceptibility to alcoholic hepatitis. *Clin Liver Dis*. 2021;25:517-535.
6. Thursz MR, Richardson P, Allison M, et al.; STOPAH Trial. Prednisolone or pentoxifylline for alcoholic hepatitis. *N Engl J Med*. 2015;372(17):1619-1628.
7. Crabb DW, Bataller R, Chalasani NP, et al. Standard definitions and common data elements for clinical trials in patients with alcoholic hepatitis: recommendation from the NIAAA Alcoholic Hepatitis Consortia. *Gastroenterology*. 2016;150(4):785-790.
8. Sehrawat TS, Liu M, Shah VH. The knowns and unknowns of treatment for alcoholic hepatitis. *Lancet Gastroenterol Hepatol*. 2020;5(5):494-506.
9. Louvet A, Labreuche J, Artru F, et al. Main drivers of outcome differ between short term and long term in severe alcoholic hepatitis: a prospective study. *Hepatology*. 2017;66(5):1464-1473.
10. Arab JP, Arrese M, Singal AK. Diagnosis of alcohol-associated hepatitis: when is liver biopsy required? *Clin Liver Dis*. 2021;25(3):571-584.
11. Biggins SW, Angeli P, Garcia-Tsao G, et al. Diagnosis, evaluation, and management of ascites, spontaneous bacterial peritonitis and hepatorenal

treatment recommendations for comorbidities and complications in patients with alcoholic hepatitis.<sup>11,36-40</sup> Early gastroenterology/hepatology, nephrology, intensive care, and palliative care consultations should be obtained as appropriate. Goals of care should be addressed with the patient and family early in the course of illness.

**Follow-Up**

Ongoing treatment of alcohol use disorder is paramount to long-term survival of patients with alcoholic hepatitis.<sup>1,11,25,26</sup> Alcohol rehabilitation is associated with a decrease in hospital readmission, relapse, and mortality.<sup>26</sup> In patients who recover from alcoholic hepatitis without residual liver impairment, several medications have demonstrated effectiveness in the treatment of alcohol use disorder, including three that are approved by the U.S. Food and Drug Administration for this indication (acamprosate, disulfiram, and naltrexone [Revia]).<sup>1</sup> These therapies are reviewed in a previous *American Family Physician* article (<https://www.aafp.org/afp/2016/0315/p457.html>) and editorial (<https://www.aafp.org/afp/2019/0615/p733.html>). In patients with continued liver impairment, acamprosate and baclofen (Lioresal) can be used based on limited data.<sup>1,8,12,25</sup>

Physicians should optimize guideline-directed medical therapy for underlying cirrhosis and ensure that patients have a gastroenterologist or hepatologist for follow-up care. Patients should be referred for liver transplant evaluation when indicated (*Table 7*).<sup>1</sup>

**Data Sources:** We searched the Cochrane Database of Systematic Reviews, PubMed Clinical Queries (search words: acute hepatitis, alcoholic and diagnosis and disease management), and Ovid (search words: acute hepatitis, alcoholic and diagnosis

## ALCOHOLIC HEPATITIS

syndrome: 2021 practice guidance by the American Association for the Study of Liver Diseases. *Hepatology*. 2021;74(2):1014-1048.

12. Singal AK, Mathurin P. Diagnosis and treatment of alcohol-associated liver disease: a review. *JAMA*. 2021;326(2):165-176.
13. Åberg F, Helenius-Hietala J, Puukka P, et al. Interaction between alcohol consumption and metabolic syndrome in predicting severe liver disease in the general population. *Hepatology*. 2018;67(6):2141-2149.
14. Bradley KA, DeBenedetti AF, Volk RJ, et al. AUDIT-C as a brief screen for alcohol misuse in primary care. *Alcohol Clin Exp Res*. 2007;31(7):1208-1217.
15. Seale JP, Boltri JM, Shellenberger S, et al. Primary care validation of a single screening question for drinkers. *J Stud Alcohol*. 2006;67(5):778-784.
16. Stewart SH, Koch DG, Burgess DM, et al. Sensitivity and specificity of urinary ethyl glucuronide and ethyl sulfate in liver disease patients. *Alcohol Clin Exp Res*. 2013;37(1):150-155.
17. Andresen-Streichert H, Beres Y, Weinmann W, et al. Improved detection of alcohol consumption using the novel marker phosphatidylethanol in the transplant setting: results of a prospective study. *Transpl Int*. 2017;30(6):611-620.
18. Louvet A, Naveau S, Abdelnour M, et al. The Lille model: a new tool for therapeutic strategy in patients with severe alcoholic hepatitis treated with steroids. *Hepatology*. 2007;45(6):1348-1354.
19. Maddrey WC, Boitnott JK, Bedine MS, et al. Corticosteroid therapy of alcoholic hepatitis. *Gastroenterology*. 1978;75(2):193-199.
20. Srikureja W, Kyulo NL, Runyon BA, et al. MELD score is a better prognostic model than Child-Turcotte-Pugh score or Discriminant Function score in patients with alcoholic hepatitis. *J Hepatol*. 2005;42(5):700-706.
21. Dunn W, Jamil LH, Brown LS, et al. MELD accurately predicts mortality in patients with alcoholic hepatitis. *Hepatology*. 2005;41(2):353-358.
22. Carithers RL Jr, Herlong HF, Diehl AM, et al. Methylprednisolone therapy in patients with severe alcoholic hepatitis. A randomized multicenter trial. *Ann Intern Med*. 1989;110(9):685-690.
23. Durand F, Valla D. Assessment of the prognosis of cirrhosis: Child-Pugh versus MELD. *J Hepatol*. 2005;42(suppl 1):S100-S107.
24. Mitra A, Myers L, Ahn J. Assessing the severity and prognosis of alcoholic hepatitis. *Clin Liver Dis*. 2021;25(3):585-593.
25. European Association for the Study of the Liver. EASL clinical practice guidelines: management of alcohol-related liver disease. *J Hepatol*. 2018;69(1):154-181.
26. Peeraphatdit TB, Kamath PS, Karpyak VM, et al. Alcohol rehabilitation within 30 days of hospital discharge is associated with reduced readmission, relapse, and death in patients with alcoholic hepatitis. *Clin Gastroenterol Hepatol*. 2020;18(2):477-485.e5.
27. Reoux JP, Miller K. Routine hospital alcohol detoxification practice compared to symptom triggered management with an Objective Withdrawal Scale (CIWA-Ar). *Am J Addict*. 2000;9(2):135-144.
28. McClain CJ, Rios CD, Condon S, et al. Malnutrition and alcohol-associated hepatitis. *Clin Liver Dis*. 2021;25(3):557-570.
29. Plauth M, Cabré E, Riggio O, et al.; German Society for Nutritional Medicine; European Society for Parenteral and Enteral Nutrition. ESPEN guidelines on enteral nutrition: liver disease. *Clin Nutr*. 2006;25(2):285-294.
30. Moreno C, Deltenre P, Senterre C, et al. Intensive enteral nutrition is ineffective for patients with severe alcoholic hepatitis treated with corticosteroids. *Gastroenterology*. 2016;150(4):903-10.e8.
31. Louvet A, Thursz MR, Kim DJ, et al. Corticosteroids reduce risk of death within 28 days for patients with severe alcoholic hepatitis, compared with pentoxifylline or placebo—a meta-analysis of individual data from controlled trials. *Gastroenterology*. 2018;155(2):458-468.e8.
32. Maddur H. Current therapies for alcohol-associated hepatitis. *Clin Liver Dis*. 2021;25(3):595-602.
33. Garcia-Saenz-de-Sicilia M, Duvoor C, Altamirano J, et al. A day-4 Lille model predicts response to corticosteroids and mortality in severe alcoholic hepatitis [published correction appears in *Am J Gastroenterol*. 2017;112(4):666]. *Am J Gastroenterol*. 2017;112(2):306-315.
34. Nguyen-Khac E, Thevenot T, Piquet MA, et al.; AAH-NAC Study Group. Glucocorticoids plus *N*-acetylcysteine in severe alcoholic hepatitis. *N Engl J Med*. 2011;365(19):1781-1789.
35. Goel A, Daugherty T. Selection criteria for liver transplantation for acute alcohol-associated hepatitis. *Clin Liver Dis*. 2021;25(3):635-644.
36. European Association for the Study of the Liver. EASL clinical practice guidelines for the management of patients with decompensated cirrhosis [published correction appears in *J Hepatol*. 2018;69(5):1207]. *J Hepatol*. 2018;69(2):406-460.
37. Garcia-Tsao G, Abraldes JG, Berzigotti A, et al. Portal hypertensive bleeding in cirrhosis: risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the Study of Liver Diseases [published correction appears in *Hepatology*. 2017;66(1):304]. *Hepatology*. 2017;65(1):310-335.
38. Vilstrup H, Amodio P, Bajaj J, et al. Hepatic encephalopathy in chronic liver disease: 2014 practice guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver. *Hepatology*. 2014;60(2):715-735.
39. Runyon BA; American Association for the Study of Liver Diseases. Management of adult patients with ascites due to cirrhosis: update 2012. Accessed May 19, 2021. [https://www.aasld.org/sites/default/files/2019-06/141020\\_Guideline\\_Ascites\\_4UFB\\_2015.pdf](https://www.aasld.org/sites/default/files/2019-06/141020_Guideline_Ascites_4UFB_2015.pdf)
40. Aithal GP, Palaniyappan N, China L, et al. Guidelines on the management of ascites in cirrhosis. *Gut*. 2021;70(1):9-29.